As the second largest biopharmaceutical market, China presents tremendous opportunity, but companies will need to mature medical affairs teams quickly as the market continues to evolve. To strengthen their medical affairs teams, pharmaceutical companies will need to be creative with their physician and stakeholder engagement models, as well as cultivating the local talent.

Polpharma Biologics is making strategic moves to become a truly integrated CDMO by bringing its Dutch Bioceros subsidiary under the Polpharma Biologics brand.

With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.